Polaris Venture Management Co. V, L.L.C. Activity Q1 2014-Q3 2021

Add to watchlist

Q3 2021

			Value		Shares		↓ Weighting
FATE	Exit	Fate Therapeutics, Inc.	$0	–	-569,889	–	-79.24%	–

Q2 2021

			Value		Shares		↓ Weighting
FATE	New	Fate Therapeutics, Inc.	$49,461,000	–	569,889	–	79.24%	–
LYRA	New	Lyra Therapeutics, Inc.	$8,840,000	–	1,100,852	–	14.16%	–
XFOR	New	x4 Pharmaceuticals Inc.	$2,025,000	–	311,492	–	3.24%	–
LIFE	New	Atyr Pharma Inc.	$637,000	–	130,572	–	1.02%	–
DARE	New	Dare Bioscience, Inc.	$617,000	–	326,240	–	0.99%	–
GNCA	New	Genocea Biosciences, Inc.	$462,000	–	197,345	–	0.74%	–
PULM	New	Pulmatrix, Inc.	$374,000	–	359,441	–	0.60%	–

Q4 2020

			Value		Shares		↓ Weighting
DARE	Exit	Dare Bioscience, Inc.	$0	–	-326,240	–	-0.54%	–
LIFE	Exit	Atyr Pharma Inc.	$0	–	-130,572	–	-0.70%	–
PULM	Exit	Pulmatrix, Inc.	$0	–	-359,441	–	-0.71%	–
GNCA	Exit	Genocea Biosciences, Inc.	$0	–	-197,345	–	-0.74%	–
XFOR	Exit	x4 Pharmaceuticals Inc.	$0	–	-311,492	–	-3.48%	–
STIM	Exit	Neuronetics, Inc.	$0	–	-732,583	–	-5.87%	–
SELB	Exit	Selecta Biosciences, Inc.	$0	–	-2,773,479	–	-11.34%	–
LYRA	Exit	Lyra Therapeutics, Inc.	$0	–	-1,100,852	–	-20.29%	–
FATE	Exit	Fate Therapeutics, Inc.	$0	–	-854,836	–	-56.34%	–

Q3 2020

			Value		Shares		↓ Weighting
FATE	Sell	Fate Therapeutics, Inc.	$34,168,000	-12.6%	854,836	-25.0%	56.34%	+85.1%
GNCA	Sell	Genocea Biosciences, Inc.	$452,000	-20.1%	197,345	-19.8%	0.74%	+68.9%
PULM	Buy	Pulmatrix, Inc.	$428,000	-30.7%	359,441	+0.0%	0.71%	+46.8%
DARE	Sell	Dare Bioscience, Inc.	$326,000	+0.9%	326,240	-0.0%	0.54%	+114.3%
	Exit	Phreesia, Inc.	$0	–	-2,214,092	–	-48.73%	–

Q2 2020

			Value		Shares		↓ Weighting
	New	Phreesia, Inc.	$62,615,000	–	2,214,092	–	48.73%	–
FATE	New	Fate Therapeutics, Inc.	$39,106,000	–	1,139,783	–	30.44%	–
LYRA	New	Lyra Therapeutics, Inc.	$12,484,000	–	1,100,852	–	9.72%	–
SELB	New	Selecta Biosciences, Inc.	$7,877,000	–	2,773,479	–	6.13%	–
XFOR	New	x4 Pharmaceuticals Inc.	$2,903,000	–	311,492	–	2.26%	–
STIM	New	Neuronetics, Inc.	$1,414,000	–	732,583	–	1.10%	–
PULM	New	Pulmatrix, Inc.	$618,000	–	359,439	–	0.48%	–
LIFE	New	Atyr Pharma Inc.	$580,000	–	130,572	–	0.45%	–
GNCA	New	Genocea Biosciences, Inc.	$566,000	–	246,078	–	0.44%	–
DARE	New	Dare Bioscience, Inc.	$323,000	–	326,243	–	0.25%	–

Q4 2019

			Value		Shares		↓ Weighting
DARE	Exit	Dare Bioscience, Inc.	$0	–	-326,243	–	-0.14%	–
PULM	Exit	Pulmatrix, Inc.	$0	–	-359,439	–	-0.17%	–
LIFE	Exit	Atyr Pharma Inc.	$0	–	-130,571	–	-0.26%	–
GNCA	Exit	Genocea Biosciences, Inc.	$0	–	-246,078	–	-0.41%	–
XFOR	Exit	x4 Pharmaceuticals Inc.	$0	–	-311,492	–	-2.25%	–
KALA	Exit	Kala Pharmaceuticals, Inc.	$0	–	-1,197,032	–	-2.59%	–
SELB	Exit	Selecta Biosciences, Inc.	$0	–	-2,773,479	–	-2.76%	–
STIM	Exit	Neuronetics, Inc.	$0	–	-732,583	–	-3.46%	–
FATE	Exit	Fate Therapeutics, Inc.	$0	–	-1,139,783	–	-10.06%	–
CDLX	Exit	Cardlytics, Inc.	$0	–	-1,508,065	–	-28.72%	–
	Exit	Phreesia, Inc.	$0	–	-3,571,213	–	-49.19%	–

Q3 2019

			Value		Shares		↓ Weighting
	New	Phreesia, Inc.	$86,566,000	–	3,571,213	–	49.19%	–
CDLX	Sell	Cardlytics, Inc.	$50,550,000	-14.6%	1,508,065	-33.8%	28.72%	-38.2%
FATE	Sell	Fate Therapeutics, Inc.	$17,701,000	-40.8%	1,139,783	-22.6%	10.06%	-57.2%
STIM	Sell	Neuronetics, Inc.	$6,088,000	-34.4%	732,583	-1.3%	3.46%	-52.6%
KALA	Sell	Kala Pharmaceuticals, Inc.	$4,555,000	-61.6%	1,197,032	-35.6%	2.59%	-72.2%
PULM	Buy	Pulmatrix, Inc.	$294,000	-11.2%	359,439	+0.0%	0.17%	-35.8%
TRVN	Exit	Trevena, Inc.	$0	–	-2,053,540	–	-1.66%	–
TTOO	Exit	T2 Biosystems, Inc.	$0	–	-1,841,924	–	-2.43%	–

Q2 2019

			Value		Shares		↓ Weighting
CDLX	New	Cardlytics, Inc.	$59,165,000	–	2,277,342	–	46.48%	–
FATE	New	Fate Therapeutics, Inc.	$29,906,000	–	1,473,186	–	23.49%	–
KALA	New	Kala Pharmaceuticals, Inc.	$11,851,000	–	1,857,582	–	9.31%	–
STIM	New	Neuronetics, Inc.	$9,286,000	–	742,289	–	7.30%	–
SELB	New	Selecta Biosciences, Inc.	$4,965,000	–	2,773,479	–	3.90%	–
XFOR	New	x4 Pharmaceuticals Inc	$4,672,000	–	311,492	–	3.67%	–
TTOO	New	T2 Biosystems, Inc.	$3,094,000	–	1,841,924	–	2.43%	–
TRVN	New	Trevena, Inc.	$2,115,000	–	2,053,540	–	1.66%	–
GNCA	New	Genocea Biosciences, Inc.	$965,000	–	246,078	–	0.76%	–
LIFE	New	Atyr Pharma Inc.	$670,000	–	130,571	–	0.53%	–
PULM	New	Pulmatrix, Inc.	$331,000	–	359,438	–	0.26%	–
DARE	New	Dare Bioscience, Inc.	$277,000	–	326,243	–	0.22%	–

Q4 2018

			Value		Shares		↓ Weighting
DARE	Exit	Dare Bioscience, Inc.	$0	–	-326,243	–	-0.16%	–
PULM	Exit	Pulmatrix, Inc.	$0	–	-3,594,381	–	-0.67%	–
LIFE	Exit	Atyr Pharma Inc.	$0	–	-1,827,992	–	-0.74%	–
GNCA	Exit	Genocea Biosciences, Inc.	$0	–	-1,968,606	–	-0.77%	–
ASNS	Exit	Arsanis, Inc.	$0	–	-1,868,957	–	-1.52%	–
TRVN	Exit	Trevena, Inc.	$0	–	-2,053,540	–	-2.18%	–
TTOO	Exit	T2 Biosystems, Inc.	$0	–	-1,841,924	–	-6.87%	–
KALA	Exit	Kala Pharmaceuticals, Inc.	$0	–	-1,857,582	–	-9.18%	–
SELB	Exit	Selecta Biosciences, Inc.	$0	–	-1,606,813	–	-12.51%	–
STIM	Exit	Neuronetics, Inc.	$0	–	-824,765	–	-13.24%	–
FATE	Exit	Fate Therapeutics, Inc.	$0	–	-2,473,186	–	-20.17%	–
CDLX	Exit	Cardlytics, Inc.	$0	–	-2,552,626	–	-32.00%	–

Q3 2018

			Value		Shares		↓ Weighting
CDLX	Sell	Cardlytics, Inc.	$63,918,000	+11.4%	2,552,626	-3.2%	32.00%	+2.4%

Q2 2018

			Value		Shares		↓ Weighting
CDLX	New	Cardlytics, Inc.	$57,365,000	–	2,636,262	–	31.26%	–
FATE	New	Fate Therapeutics, Inc.	$28,046,000	–	2,473,186	–	15.28%	–
KALA	New	Kala Pharmaceuticals, Inc.	$25,505,000	–	1,857,582	–	13.90%	–
STIM	New	Neuronetics, Inc.	$21,947,000	–	824,765	–	11.96%	–
SELB	New	Selecta Biosciences, Inc.	$21,290,000	–	1,606,813	–	11.60%	–
TTOO	New	T2 Biosystems, Inc.	$14,257,000	–	1,841,924	–	7.77%	–
ASNS	New	Arsanis, Inc.	$6,784,000	–	1,868,957	–	3.70%	–
TRVN	New	Trevena, Inc.	$2,957,000	–	2,053,540	–	1.61%	–
GNCA	New	Genocea Biosciences, Inc.	$1,685,000	–	1,968,606	–	0.92%	–
LIFE	New	Atyr Pharma Inc.	$1,663,000	–	1,827,992	–	0.91%	–
PULM	New	Pulmatrix, Inc.	$1,617,000	–	3,594,381	–	0.88%	–
DARE	New	Dare Bioscience, Inc.	$382,000	–	326,243	–	0.21%	–

Q4 2017

			Value		Shares		↓ Weighting
DARE	Exit	Dare Bioscience, Inc.	$0	–	-328,752	–	-0.88%	–
GNCA	Exit	Genocea Biosciences, Inc.	$0	–	-1,968,606	–	-2.47%	–
TRVN	Exit	Trevena, Inc.	$0	–	-2,053,540	–	-4.50%	–
PULM	Exit	Pulmatrix Inc.	$0	–	-3,607,996	–	-6.36%	–
TTOO	Exit	T2 Biosystems, Inc.	$0	–	-1,875,524	–	-6.77%	–
LIFE	Exit	Atyr Pharma Inc.	$0	–	-1,827,992	–	-7.94%	–
FATE	Exit	Fate Therapeutics, Inc.	$0	–	-2,473,186	–	-8.42%	–
SELB	Exit	Selecta Biosciences, Inc.	$0	–	-1,627,527	–	-25.53%	–
KALA	Exit	Kala Pharmaceuticals, Inc.	$0	–	-1,890,913	–	-37.13%	–

Q3 2017

			Value		Shares		↓ Weighting
KALA	New	Kala Pharmaceuticals, Inc.	$43,188,000	–	1,890,913	–	37.13%	–
SELB	Sell	Selecta Biosciences, Inc.	$29,702,000	-22.3%	1,627,527	-15.4%	25.53%	-35.4%
DARE	New	Dare Bioscience, Inc.	$1,026,000	–	328,752	–	0.88%	–
CERU	Exit	Cerulean Pharma Inc	$0	–	-3,287,529	–	-15.10%	–

Q2 2017

			Value		Shares		↓ Weighting
SELB	New	Selecta Biosciences, Inc.	$38,213,000	–	1,924,151	–	39.54%	–
CERU	New	Cerulean Pharma Inc	$14,596,000	–	3,287,529	–	15.10%	–
GNCA	New	Genocea Biosciences, Inc.	$10,276,000	–	1,968,606	–	10.63%	–
PULM	New	Pulmatrix Inc.	$8,587,000	–	3,607,996	–	8.88%	–
FATE	New	Fate Therapeutics, Inc.	$8,013,000	–	2,473,186	–	8.29%	–
LIFE	New	Atyr Pharma Inc.	$6,215,000	–	1,827,992	–	6.43%	–
TTOO	New	T2 Biosystems, Inc.	$6,020,000	–	1,875,524	–	6.23%	–
TRVN	New	Trevena, Inc.	$4,723,000	–	2,053,540	–	4.89%	–

Q4 2016

			Value		Shares		↓ Weighting
CERU	Exit	Cerulean Pharma Inc	$0	–	-3,287,529	–	-3.63%	–
LIFE	Exit	Atyr Pharma Inc.	$0	–	-1,827,992	–	-6.14%	–
PULM	Exit	Pulmatrix Inc.	$0	–	-3,607,996	–	-6.28%	–
OCUL	Exit	Ocular Therapeutix, Inc.	$0	–	-998,713	–	-7.24%	–
FATE	Exit	Fate Therapeutics, Inc.	$0	–	-2,473,186	–	-8.15%	–
GNCA	Exit	Genocea Biosciences, Inc.	$0	–	-1,968,606	–	-10.64%	–
TTOO	Exit	T2 Biosystems, Inc.	$0	–	-1,875,524	–	-14.34%	–
TRVN	Exit	Trevena, Inc.	$0	–	-2,053,540	–	-14.63%	–
SELB	Exit	Selecta Biosciences, Inc.	$0	–	-1,924,151	–	-28.95%	–

Q3 2016

			Value		Shares		↓ Weighting
TRVN	Sell	Trevena, Inc.	$13,861,000	-3.1%	2,053,540	-9.5%	14.63%	-4.7%
BINDQ	Exit	Bind Therapeutics, Inc.	$0	–	-2,018,253	–	-0.85%	–

Q2 2016

			Value		Shares		↓ Weighting
SELB	New	Selecta Biosciences, Inc.	$26,919,000	–	1,924,151	–	28.90%	–
TTOO	New	T2 Biosystems, Inc.	$14,798,000	–	1,875,524	–	15.89%	–
TRVN	New	Trevena, Inc.	$14,303,000	–	2,270,319	–	15.35%	–
GNCA	New	Genocea Biosciences, Inc.	$8,071,000	–	1,968,606	–	8.66%	–
PULM	New	Pulmatrix Inc.	$7,072,000	–	3,607,996	–	7.59%	–
CERU	New	Cerulean Pharma Inc	$6,970,000	–	3,287,529	–	7.48%	–
LIFE	New	Atyr Pharma Inc.	$5,082,000	–	1,827,992	–	5.46%	–
OCUL	New	Ocular Therapeutix, Inc.	$4,944,000	–	998,713	–	5.31%	–
FATE	New	Fate Therapeutics, Inc.	$4,204,000	–	2,473,186	–	4.51%	–
BINDQ	New	Bind Therapeutics, Inc.	$789,000	–	2,018,253	–	0.85%	–

Q4 2015

			Value		Shares		↓ Weighting
BINDQ	Exit	Bind Therapeutics, Inc.	$0	–	-2,018,253	–	-6.13%	–
CERU	Exit	Cerulean Pharma Inc	$0	–	-3,287,529	–	-8.20%	–
FATE	Exit	Fate Therapeutics, Inc.	$0	–	-2,473,186	–	-8.98%	–
GNCA	Exit	Genocea Biosciences, Inc.	$0	–	-1,968,606	–	-9.19%	–
OCUL	Exit	Ocular Therapeutix, Inc.	$0	–	-1,230,009	–	-11.78%	–
TTOO	Exit	T2 Biosystems, Inc.	$0	–	-2,018,450	–	-12.05%	–
PULM	Exit	Pulmatrix Inc.	$0	–	-3,607,996	–	-12.07%	–
LIFE	Exit	Atyr Pharma Inc.	$0	–	-1,827,992	–	-12.78%	–
TRVN	Exit	Trevena, Inc.	$0	–	-2,669,280	–	-18.82%	–

Q3 2015

			Value		Shares		↓ Weighting
TRVN	Sell	Trevena, Inc.	$27,627,000	+17.1%	2,669,280	-29.2%	18.82%	+78.9%
TTOO	Sell	T2 Biosystems, Inc.	$17,682,000	-52.0%	2,018,450	-11.1%	12.05%	-26.7%

Q2 2015

			Value		Shares		↓ Weighting
TTOO	New	T2 Biosystems, Inc.	$36,835,000	–	2,269,578	–	16.43%	–
PULM	New	Pulmatrix Inc.	$34,637,000	–	3,607,996	–	15.45%	–
LIFE	New	Atyr Pharma Inc.	$33,854,000	–	1,827,992	–	15.10%	–
GNCA	New	Genocea Biosciences, Inc.	$27,029,000	–	1,968,606	–	12.05%	–
OCUL	New	Ocular Therapeutix, Inc.	$25,867,000	–	1,230,009	–	11.54%	–
TRVN	New	Trevena, Inc.	$23,596,000	–	3,769,280	–	10.52%	–
FATE	New	Fate Therapeutics, Inc.	$16,002,000	–	2,473,186	–	7.14%	–
CERU	New	Cerulean Pharma Inc	$15,123,000	–	3,287,529	–	6.74%	–
BINDQ	New	Bind Therapeutics, Inc.	$11,282,000	–	2,018,253	–	5.03%	–

Q4 2014

			Value		Shares		↓ Weighting
FATE	Exit	Fate Therapeutics, Inc.	$0	–	-2,473,186	–	-9.73%	–
CERU	Exit	Cerulean Pharma Inc	$0	–	-3,287,529	–	-10.71%	–
BINDQ	Exit	Bind Therapeutics, Inc.	$0	–	-2,018,253	–	-13.38%	–
GNCA	Exit	Genocea Biosciences, Inc.	$0	–	-2,055,230	–	-14.35%	–
TRVN	Exit	Trevena, Inc.	$0	–	-3,769,280	–	-18.68%	–
TTOO	Exit	T2 Biosystems, Inc.	$0	–	-2,374,571	–	-33.15%	–

Q3 2014

			Value		Shares		↓ Weighting
TTOO	New	T2 Biosystems, Inc.	$42,956,000	–	2,374,571	–	33.15%	–
TRVN	Sell	Trevena, Inc.	$24,199,000	+12.4%	3,769,280	-1.1%	18.68%	+6.4%
GNCA	Sell	Genocea Biosciences, Inc.	$18,600,000	-53.4%	2,055,230	-3.5%	14.35%	-55.9%

Q2 2014

			Value		Shares		↓ Weighting
GNCA	New	Genocea Biosciences, Inc.	$39,913,000	–	2,128,678	–	32.52%	–
BINDQ	New	Bind Therapeutics, Inc.	$26,600,000	–	2,018,253	–	21.68%	–
TRVN	New	Trevena, Inc.	$21,536,000	–	3,811,682	–	17.55%	–
CERU	New	Cerulean Pharma Inc	$19,068,000	–	3,287,529	–	15.54%	–
FATE	New	Fate Therapeutics, Inc.	$15,606,000	–	2,473,186	–	12.72%	–

Compare quarters

Export Polaris Venture Management Co. V, L.L.C.'s holdings